ACADIA PHARMACEUTICALS INC
Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold 20,141 shares of ACADIA PHARMACEUTICALS INC (ACAD) at an average of $29.16 ($29.00–$29.34, $0.59M total) across 3 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
Acadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.
Acadia Pharmaceuticals (ACAD) shares rose 6.1% to $28.80 after earnings. For Q2 2026, revenue was $307.96 million (up from $264.57 million) and net income was $31.5 million (up from $26.67 million). The article cites a P/E of 13 and a DCF fair value estimate of $87.67 per share, with focus on DAYBUE, NUPLAZID and remlifanserin pipeline milestones.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ACAD (ACADIA PHARMACEUTICALS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ACAD coverage spans financial news, insider activity and earnings.
In the last 30 days, ACAD insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.0M). The most active reporter was Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, with 3 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is an insider sale disclosure, not a fundamental update, but it can modestly affect near-term sentiment and positioning.
Guidance upside plus a clearer EU regulatory path for DAYBUE can re-rate near-term revenue expectations and de-risk commercialization timing.
Near-term upside bias from reported Q2 profitability and raised DAYBUE 2026 revenue guidance, but the stock remains exposed to binary remlifanserin efficacy risk.
Guidance raise plus updated clinical timeline (Phase 2 topline expected Sep-Oct 2026) increases near-term visibility on revenue trajectory and pipeline optionality.
Analyst target hike is positive, but reserve uncertainty is a valuation overhang that can limit multiple expansion until claims stabilize.
alphai scores every news story that mentions ACAD with an AI model for sentiment and relevance, and aggregates insider trades from ACADIA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) sold 20,141 shares of ACADIA PHARMACEUTICALS INC (ACAD) at an average of $29.16 ($29.00–$29.34, $0.59M total) across 3 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readAcadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.
6 min readAcadia Pharmaceuticals (ACAD) shares rose 6.1% to $28.80 after earnings. For Q2 2026, revenue was $307.96 million (up from $264.57 million) and net income was $31.5 million (up from $26.67 million). The article cites a P/E of 13 and a DCF fair value estimate of $87.67 per share, with focus on DAYBUE, NUPLAZID and remlifanserin pipeline milestones.
4 min readACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 acad-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE ® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID ® GAAP net
6 min readite opens. That matters because behavioral-health facilities carry a lot of fixed costs (staffing and buildings), so higher patient volumes can push profits up quickly once the doors are open. The catch is risk that has nothing to do with demand. UBS highlighted a $28.6 million increase in professional and general liability reserves, money set aside for potential future claims.
2 min readAcadia Pharmaceuticals’ investigational drug remlifanserin for Alzheimer’s disease psychosis received FDA Fast Track designation, and the company provided updated timing for its RADIANT trial program. The stock closed at $24.84. The article cites analyst targets around $32.80 and a “fair value” narrative near $28.75, implying upside versus the close.
5 min readAcadia Pharmaceuticals (NASDAQ:ACAD) insider James Kihara, Principal Accounting Officer, sold 11,421 shares of Acadia common stock on June 26, 2026 for about $298,000 at a weighted average price of $26.08, per an SEC Form 4. The sale was 46.6% of his direct holdings, leaving 13,088 shares. Acadia reported $268.1M Q1 revenue (2026) and $1.10B TTM revenue.
5 min readKihara James (PRINCIPAL ACCOUNTING OFFICER) sold 5,401 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $21.18 ($0.11M total) on 2026-05-26.
1 min readACADIA Pharmaceuticals (ACAD) has seen a 19.2% stock decline year-to-date in 2026, dropping to $21.57 per share amidst competitive pressures in the central nervous system (CNS) disorder treatment market. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $31.00, suggesting a potential 43.7% upside. The company remains profitable with a 34.30% net margin, and its decline is attributed more to broader sector volatility than company-specific issues.
4 min readACADIA Pharmaceuticals (ACAD) reported mixed Q1 2026 results with 10% revenue growth but weaker earnings and a setback for trofinetide in Europe. Despite these challenges, ACADIA's stock shows a 33.28% one-year return and analysts see the company as undervalued with a fair value of $28.75. The valuation hinges on balancing clinical ambition with financial discipline and disciplined execution in its specialized neurology and rare disease focus.
4 min read
